144 related articles for article (PubMed ID: 31685378)
1. Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy.
Nandakumar B; Kumar SK; Dispenzieri A; Buadi FK; Dingli D; Lacy MQ; Hayman SR; Kapoor P; Leung N; Fonder A; Hobbs M; Hwa YL; Muchtar E; Warsame R; Kourelis TV; Russell S; Lust JA; Lin Y; Go RS; Siddiqui M; Zeldenrust S; Kyle RA; Gertz MA; Rajkumar SV; Gonsalves WI
Clin Lymphoma Myeloma Leuk; 2020 Jan; 20(1):53-56. PubMed ID: 31685378
[TBL] [Abstract][Full Text] [Related]
2. Outcome and characteristics of nonsecretory multiple myeloma compared with secretory multiple myeloma: a retrospective multicenter study from China.
Sun H; Liu A; Liu L; Wang W; Cai Z; Yan H; Chen L; Gao G; Wang F; Liao A; Chen B; Feng J; Li J; Huang DP; Gao D; Zhang QK; Luo J; Fu R; Du J; Lu J
BMC Cancer; 2023 Oct; 23(1):930. PubMed ID: 37784037
[TBL] [Abstract][Full Text] [Related]
3. Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation.
Chakraborty R; Muchtar E; Kumar SK; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Warsame R; Kourelis T; Gonsalves W; Gertz MA
Br J Haematol; 2018 Jul; 182(1):71-77. PubMed ID: 29707759
[TBL] [Abstract][Full Text] [Related]
4. Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents.
Avet-Loiseau H; Facon T
Leukemia; 2018 Jun; 32(6):1267-1276. PubMed ID: 29720731
[TBL] [Abstract][Full Text] [Related]
5. Higher Decorin Levels in Bone Marrow Plasma Are Associated with Superior Treatment Response to Novel Agent-Based Induction in Patients with Newly Diagnosed Myeloma - A Retrospective Study.
Huang SY; Lin HH; Yao M; Tang JL; Wu SJ; Hou HA; Chou WC; Chou SC; Hsu SC; Ko BS; Lu HY; Tsay W; Tien HF
PLoS One; 2015; 10(9):e0137552. PubMed ID: 26379028
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.
Merz M; Salwender H; Haenel M; Mai EK; Bertsch U; Kunz C; Hielscher T; Blau IW; Scheid C; Hose D; Seckinger A; Jauch A; Hillengass J; Raab MS; Schurich B; Munder M; Schmidt-Wolf IG; Gerecke C; Lindemann HW; Zeis M; Weisel K; Duerig J; Goldschmidt H
Haematologica; 2015 Jul; 100(7):964-9. PubMed ID: 25840597
[TBL] [Abstract][Full Text] [Related]
7. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
[TBL] [Abstract][Full Text] [Related]
8. Non-secretory multiple myeloma with diagnostic challenges.
Hamidah NH; Azma RZ; Ezalia E; Das S; Umar NA; Swaminathan M; Mohamed Z; Abdul Wahid SF
Clin Ter; 2010; 161(5):445-8. PubMed ID: 20949241
[TBL] [Abstract][Full Text] [Related]
9. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial.
Einsele H; Engelhardt M; Tapprich C; Müller J; Liebisch P; Langer C; Kropff M; Mügge LO; Jung W; Wolf HH; Metzner B; Hart C; Gramatzki M; Hertenstein B; Pfreundschuh M; Rösler W; Fischer T; Maschmeyer G; Kanz L; Hess G; Jäger E; Bentz M; Dürk HA; Salwender H; Hebart H; Straka C; Knop S
Br J Haematol; 2017 Nov; 179(4):586-597. PubMed ID: 28961309
[TBL] [Abstract][Full Text] [Related]
11. Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents.
Merz M; Neben K; Raab MS; Sauer S; Egerer G; Hundemer M; Hose D; Kunz C; Heiß C; Ho AD; Goldschmidt H; Hillengass J
Ann Oncol; 2014 Jan; 25(1):189-95. PubMed ID: 24356629
[TBL] [Abstract][Full Text] [Related]
12. Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation.
Kazmi SM; Nusrat M; Gunaydin H; Cornelison AM; Shah N; Kebriaei P; Nieto Y; Parmar S; Popat UR; Oran B; Shah JJ; Orlowski RZ; Champlin RE; Qazilbash MH; Bashir Q
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):687-93. PubMed ID: 26361647
[TBL] [Abstract][Full Text] [Related]
13. Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma.
Gonsalves WI; Rajkumar SV; Gupta V; Morice WG; Timm MM; Singh PP; Dispenzieri A; Buadi FK; Lacy MQ; Kapoor P; Gertz MA; Kumar SK
Leukemia; 2014 Oct; 28(10):2060-5. PubMed ID: 24618735
[TBL] [Abstract][Full Text] [Related]
14. Socioeconomic Status Is an Independent Prognostic Factor for Overall Survival in Patients With Multiple Myeloma: Real-World Data From a Cohort of 223 Patients.
Intzes S; Symeonidou M; Zagoridis K; Bezirgiannidou Z; Pentidou A; Vrachiolias G; Seimenis I; Kotsianidis I; Spanoudakis E
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):704-711. PubMed ID: 32653455
[TBL] [Abstract][Full Text] [Related]
15. Non-secretory multiple myeloma: from biology to clinical management.
Dupuis MM; Tuchman SA
Onco Targets Ther; 2016; 9():7583-7590. PubMed ID: 28008276
[TBL] [Abstract][Full Text] [Related]
16. Real world outcomes with Bortezomib Thalidomide dexamethasone and Cyclophosphamide Bortezomib dexamethasone induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A Retrospective Cohort Study from Grupo Argentino de Mieloma Múltiple.
Schütz NP; Ochoa P; Duarte P; Remaggi G; Yantorno S; Corzo A; Zabaljauregui S; Shanley C; Lopresti S; Orlando S; Verri V; Quiroga L; García CA; Fernández V; Fantl D
Hematol Oncol; 2020 Aug; 38(3):363-371. PubMed ID: 32196120
[TBL] [Abstract][Full Text] [Related]
17. Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents.
Romano A; Parrinello NL; Consoli ML; Marchionni L; Forte S; Conticello C; Pompa A; Corso A; Milone G; Di Raimondo F; Borrello I
Ann Hematol; 2015 Nov; 94(11):1875-83. PubMed ID: 26223359
[TBL] [Abstract][Full Text] [Related]
18. Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies.
Zagouri F; Kastritis E; Zomas A; Terpos E; Katodritou E; Symeonidis A; Delimpasi S; Pouli A; Vassilakopoulos TP; Michalis E; Giannouli S; Kartasis Z; Christoforidou A; Kokoviadou K; Hatzimichael E; Gika D; Megalakaki C; Papaioannou M; Kyrtsonis MC; Konstantopoulos K; Dimopoulos MA;
Eur J Haematol; 2017 Nov; 99(5):409-414. PubMed ID: 28675766
[TBL] [Abstract][Full Text] [Related]
19. Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis.
Saini N; Ma J; Milton DR; Patel R; Varma A; Bashir Q; Delgado R; Mukherjee A; Rondon G; Popat UR; Hosing CM; Nieto Y; Kebriaei P; Alousi AM; Ahmed S; Tang G; Mehta R; Srour S; Khouri IF; Iyer S; Weber DM; Thomas SK; Lee HC; Manasanch EE; Patel KK; Orlowski RZ; Champlin RE; Qazilbash MH
Clin Cancer Res; 2019 Nov; 25(22):6781-6787. PubMed ID: 31481508
[TBL] [Abstract][Full Text] [Related]
20. Case report. Non-secretory multiple myeloma presenting with diffuse sclerosis of affected bones interspersed with osteolytic lesions.
Prasad R; Yadav RR; Singh A; Mathur SP; Mangal Y; Singh M
Br J Radiol; 2009 Feb; 82(974):e29-31. PubMed ID: 19168686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
